Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
Enzalutamide sustains survival benefit in mHSPC with over 5 years’ follow-up
“ENZAMET adds to the body of knowledge from several other pivotal trials and now informs best practices for mHSPC,” said Ian D. Davis, MBBS, PhD, FRACP, FAChPM.
Tislelizumab plus nab-paclitaxel shows promise in high-risk NMIBC
Patients in the study had tumors that were not completely resectable.
Neoadjuvant chemoimmunotherapy shows promise in MIBC
The neoadjuvant combination of the PD-1 inhibitor tislelizumab and nab-paclitaxel induced a high rate of pathologic complete response in patients with muscle-invasive bladder cancer.
Nivolumab/Cabozantinib survival benefit in RCC sustained with extended follow-up
The final overall survival analysis from the phase 3 CheckMate 9ER trial continued to show a benefit with frontline nivolumab/cabozantinib versus sunitinib in patients with advanced renal cell carcinoma.
Nivolumab/cabozantinib efficacy in RCC unaffected by prior nephrectomy status
The findings come from an exploratory subgroup analysis of the pivotal CheckMate 9-ER trial shared during the 2021 ESMO Congress.
Latest tivozanib data shared as FDA weighs kidney cancer approval
The FDA is scheduled to decide on a new drug application for tivozanib by March 31, 2021, for use in relapsed/refractory renal cell carcinoma.
2 Commerce Drive Cranbury, NJ 08512